Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)
Giovanni Martinotti, Antonio Vita, Andrea Fagiolini, et al.
Journal of Affective Disorders (2022) Vol. 319, pp. 646-654
Closed Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

The antidepressant actions of ketamine and its enantiomers
Jenessa N. Johnston, Ioline D. Henter, Carlos A. Zarate
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108431-108431
Open Access | Times Cited: 72
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression
Giovanni Martinotti, Bernardo Dell’Osso, Giorgio Di Lorenzo, et al.
Bipolar Disorders (2023) Vol. 25, Iss. 3, pp. 233-244
Open Access | Times Cited: 47
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Giacomo d’Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, et al.
European Neuropsychopharmacology (2023) Vol. 70, pp. 49-55
Closed Access | Times Cited: 38
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study
Stefania Chiappini, Giacomo d’Andrea, Sergio De Filippis, et al.
European Neuropsychopharmacology (2023) Vol. 74, pp. 15-21
Open Access | Times Cited: 30
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
Mauro Pettorruso, Roberto Guidotti, Giacomo d’Andrea, et al.
Psychiatry Research (2023) Vol. 327, pp. 115378-115378
Open Access | Times Cited: 25
The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
Giacomo d’Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, et al.
Journal of Affective Disorders (2023) Vol. 348, pp. 314-322
Closed Access | Times Cited: 24
Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group
Giacomo d’Andrea, Stefania Chiappini, Roger S. McIntyre, et al.
American Journal of Geriatric Psychiatry (2023) Vol. 31, Iss. 12, pp. 1032-1041
Open Access | Times Cited: 23
Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
Cameron N. Calder, Angela T.H. Kwan, Kayla M. Teopiz, et al.
Journal of Affective Disorders (2024) Vol. 356, pp. 753-762
Closed Access | Times Cited: 8
Trends in research on novel antidepressant treatments
Agnieszka Zelek-Molik, Ewa Litwa
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 30
Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada
Carson Chrenek, Bryan Duong, Atul Khullar, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 7
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 7
French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024
Antoine Yrondi, Hervé Javelot, Bénédicte Nobile, et al.
L Encéphale (2024)
Closed Access | Times Cited: 6
Single arketamine in treatment resistant depression: Presentation of 3 cases with regard to sick-leave duration
Adam Włodarczyk, Jakub Słupski, Joanna Szarmach, et al.
Asian Journal of Psychiatry (2024) Vol. 96, pp. 104016-104016
Open Access | Times Cited: 6
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
Roger S. McIntyre, Rakesh Jain
CNS Drugs (2024) Vol. 38, Iss. 11, pp. 869-890
Open Access | Times Cited: 6
Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel
Giuseppe Maina, Marina Rossato Adami, G. Ascione, et al.
Annals of General Psychiatry (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Comparing fast-acting interventions for treatment-resistant depression: An explorative study of accelerated HF-rTMS versus intranasal esketamine
Mauro Pettorruso, Giacomo d’Andrea, Francesco Di Carlo, et al.
Brain stimulation (2023) Vol. 16, Iss. 4, pp. 1041-1043
Open Access | Times Cited: 14
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi, et al.
CNS Drugs (2023) Vol. 37, Iss. 8, pp. 715-723
Open Access | Times Cited: 14
The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
Ludivine Boudieu, M. Mennetrier, Pierre‐Michel Llorca, et al.
Pharmaceutics (2023) Vol. 15, Iss. 12, pp. 2773-2773
Open Access | Times Cited: 13
The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
Maria Pepe, Giovanni Bartolucci, Ilaria Marcelli, et al.
Brain Sciences (2023) Vol. 13, Iss. 10, pp. 1494-1494
Open Access | Times Cited: 11
Stanford neuromodulation therapy for treatment-resistant depression: a systematic review
Xian-Jun Lan, Dong-Bin Cai, Qi-Man Liu, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 11
How different definition criteria may predict clinical outcome in treatment resistant depression: Results from a prospective real-world study
Raffaella Zanardi, Matteo Carminati, Francesco Attanasio, et al.
Psychiatry Research (2024) Vol. 334, pp. 115818-115818
Closed Access | Times Cited: 4
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Maxwell Zachary Price, Richard L. Price
Biomarkers in Neuropsychiatry (2024) Vol. 11, pp. 100104-100104
Open Access | Times Cited: 4
Research Progress in the Treatment of Depression by Acupuncture and Moxibustion Based on the Five Viscera and Its Mechanism
Ruisu Zhang, Qian Zhang, Dandan Zhang, et al.
Pharmacognosy Magazine (2025)
Open Access
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study
Natalie Mills, Stevan Nikolin, Nick Glozier, et al.
The British Journal of Psychiatry (2025), pp. 1-7
Closed Access
Page 1 - Next Page

Scroll to top